CG Oncology Q3 net loss $43.8M ($0.57/share); initiates BLA for cretostimogene

CG Oncology, Inc.

2025-Q3 EPS reported -$1.57 revenue$1,718,000

Net loss of $43.8M ($0.57 per share) for Q3 2025 vs $20.4M ($0.30) in Q3 2024.
Cash, cash equivalents and marketable securities $680.3M, sufficient to fund operations into H1 2028.
Initiated rolling BLA submission to FDA for cretostimogene monotherapy in HR BCG-unresponsive NMIBC.
R&D expenses $27.9M (up 42% YoY), G&A $23.3M (up 168% YoY) driven by clinical trials and headcount.
Completed enrollment of Phase 3 PIVOT-006 trial in IR NMIBC 10 months ahead of schedule.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-281672
form_type: 8-K
ticker: CGON
cik: 0001991792
company_name: CG Oncology, Inc.
filed_at: 2025-11-14T23:59:59+00:00
discovered_at: 2026-05-14T18:02:41.226880+00:00
generated_at: 2026-05-16T19:57:09.331636+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-281672
json_url: https://secwatch.observer/filing/0001193125-25-281672.json
markdown_url: https://secwatch.observer/filing/0001193125-25-281672.md
text_url: https://secwatch.observer/filing/0001193125-25-281672.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1991792/000119312525281672/0001193125-25-281672-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1991792/000119312525281672/ck0001991792-20251114.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-25-281672

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.